SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $11,507,522,068 |
| Positions | 84 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ASCENDIS PHARMA A/S | ASND | Common Stock | $2,742,280,613 | 10,281,496 |
| PARABILIS MEDICINES INC | PBLS | Common Stock | $791,906,364 | 28,933,371 |
| RHYTHM PHARMACEUTICALS INC | RYTM | Common Stock | $740,218,912 | 6,666,837 |
| VAXCYTE INC | PCVX | Common Stock | $667,018,440 | 11,474,599 |
| SIONNA THERAPEUTICS INC | SION | Common Stock | $435,722,930 | 9,905,045 |
| TYRA BIOSCIENCES INC | TYRA | Common Stock | $389,624,083 | 12,198,625 |
| EDGEWISE THERAPEUTICS INC | EWTX | Common Stock | $340,996,620 | 8,392,730 |
| NEWAMSTERDAM PHARMA CO NV | NAMS | Common Stock | $323,655,973 | 9,550,191 |
| HEMAB THERAPEUTICS HOLDINGS | COAG | Common Stock | $286,810,870 | 7,808,627 |
| SEPTERNA INC | SEPN | Common Stock | $234,291,284 | 6,995,858 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.